Panelists discuss how tarlatamab, a bispecific T-cell engager therapy, received accelerated approval for extensive-stage small cell lung cancer (SCLC) in May 2024, examining its mechanism of ...

Key Takeaways. Biomarker testing in SCLC is essential for personalizing treatment, though less established than in non-small cell lung cancer. Testing is usually incorporated at diagnosis or ...

A new research paper was published in Oncotarget's Volume 15 on October 11, 2024, entitled "Relationship between the expressions of DLL3, ASC1, TTF-1 and Ki-67: First steps of precision medicine ...

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced today that the Phase 3 IMforte trial has established a new milestone in the treatment of extensive-stage small cell lung cancer (ES-SCLC). The ...

New president DeMark Liggins has served with the SCLC for over 10 years. The Southern Christian Leadership Conference (SCLC) has promoted its vice president, DeMark Liggins, to lead the esteemed ...

WASHINGTON — Timing matters when it comes to combining immunotherapy with chemoradiation in limited-stage small cell lung cancer (SCLC), according to the phase 3 NRG-LU005 trial presented at the ...

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced positive results from the Phase III IMforte study of Tecentriq (atezolizumab) in combination with lurbinectedin (Zepzelca) as ...